Recent News

• 11.05.2026 - Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026
• 09.03.2026 - Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference
• 08.13.2026 - Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update
• 08.05.2026 - Grace Therapeutics Announces $10 Million Private Placement
• 07.28.2026 - Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration
• 06.18.2026 - Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update
• 04.23.2026 - Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104
• 04.14.2026 - Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026
• 03.19.2026 - Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences
• 02.25.2026 - Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Recent Filings

• 11.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.13.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.01.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.01.2026 - 4/A Statement of changes in beneficial ownership of securities
• 09.23.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.21.2026 - 4 Statement of changes in beneficial ownership of securities